成人VR视频 researchers engineer faster, more effective blood clots
Researchers at 成人VR视频 have developed a rapid way to engineer blood clots that stop severe bleeding and support tissue healing more effectively. Their technique, called 鈥渃lick clotting,鈥� links red blood cell surface proteins through a chemical reaction, resulting in a biocompatible clot that is 13 times more resistant to fracturing and four times more adhesive than natural blood clots. The team said the method could be used to develop life-saving biomaterials to help control severe bleeding, as well as benefit people with clotting disorders.
鈥淣atural blood clots can be slow to form and mechanically fragile, which limits their ability to stop severe bleeding and can compromise healing,鈥� said聽Jianyu Li,聽senior聽author and Professor of聽Mechanical聽Engineering聽and Canada Research Chair in Tissue Repair and聽Regeneration.聽鈥淥ur work shows that, when engineered appropriately, red blood cells can play a central structural role, enabling the design of stronger and more functional biomaterials.鈥澛�
聽led the research during his PhD studies at 成人VR视频. He is now a Postdoctoral Associate at聽Mass General聽Brigham and Women鈥檚 Hospital, Harvard Medical School.聽聽
Researchers at the University of British Columbia, the Medical College of Wisconsin, the University of Colorado Boulder, the University of Toronto, and the Versiti Blood Research Institute also contributed.聽
Connected by chemical reaction聽
Previous聽efforts to crosslink red blood cells used chitosan, a polymer derived from crustacean shells, but these led to brittle clots, ruptured聽cells聽and inconsistent clotting.聽In 鈥渃lick clotting,鈥� the clot structure is fundamentally strengthened聽through a聽fast, bio-safe chemical reaction that connects proteins聽on the聽red blood cell聽surface, forming a solid gel in聽just five seconds.聽
Because the聽鈥渃lick鈥� reaction聽doesn鈥檛聽interfere with normal blood chemistry, it can work alongside the body鈥檚 natural clotting process. As a result, the artificial cell鈥慴ased gel, called a 鈥渃ytogel,鈥� can be added to whole blood, where it becomes embedded within the body鈥檚 own fibrin clot.聽
鈥淭he technology enables both autologous clots (using the patient鈥檚 own blood) and allogeneic clots (using type-matched donor blood).聽Autologous clots can be prepared in approximately 20 minutes, while allogeneic clots can be prepared within about 10 minutes. Given typical clinical time constraints, this approach has strong potential for in-patient emergency care, wound聽management聽and related settings,鈥� Li said.聽聽
The results were confirmed through in vitro testing, as well as聽by聽testing on rodents.聽A highlight was the effective healing and regeneration聽observed聽in the injured liver, with performance exceeding that of the clinically used product tested in this study.聽Analysis showed聽minimal聽evidence of聽immune reactivity聽and no聽toxicity in major organs.聽
Further research required聽
The researchers say that while further study is聽required聽before the聽cytogel聽can be used in clinical settings, the聽research聽establishes聽a foundation for聽its聽design and application.聽
鈥淓ngineered blood clots have strong potential for broad clinical use and could improve outcomes across many medical situations,鈥� Li said.聽
About this study聽
鈥�,鈥� by聽厂丑耻补颈产颈苍驳听闯颈补苍驳,聽Guangyu聽Bao, Zhen Yang, Jing Wu,聽Xingwei聽Yang, Joo Eun聽June聽Kim,聽Roselyn Jiang,聽Oliver Zhan, Alexander聽Nottegar, Yin聽Liu,聽Anastasia聽Nijnik, Rong Long,聽Jianyu Li聽et al., was published in聽狈补迟耻谤别.听
The study was funded by the Canadian Institutes of Health Research and the New Frontiers in Research Fund - Exploration.